Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
ALNYLAM PHARMACEUTICALS, INC. director Margaret A. Hamburg reported equity awards consisting of common stock and stock options. She received 671 shares of common stock in the form of restricted stock units (RSUs) that each convert into one share when they vest. The RSUs will vest in full on the earlier of the first anniversary of the May 20, 2026 grant or an earlier retirement or resignation that occurs no more than 90 days before that date. She was also granted stock options for 1,441 shares of common stock at an exercise price of $298.4800 per share, with the same vesting schedule. After these awards, her directly held common stock position reported in this filing is 1,582 shares, and she holds options for 1,441 underlying shares.
ALNYLAM PHARMACEUTICALS, INC. director Olivier Brandicourt reported compensation-related equity awards, not open-market trades. He received 671 shares of common stock in the form of restricted stock units granted at no cash cost.
Brandicourt was also granted stock options for 1,441 shares of common stock at an exercise price of $298.48 per share. Both the RSUs and the options vest in full on the earlier of the first anniversary of the May 20, 2026 grant date or his earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary. Following these awards, he directly holds 1,446 common shares and 1,441 stock options.
ALNYLAM PHARMACEUTICALS, INC. director Dennis A. Ausiello reported equity awards and updated holdings. He received a grant of 671 restricted stock units, each representing one future share of common stock, which will vest in full on the first anniversary of the grant date or upon certain earlier retirement or resignation conditions. He was also granted stock options on 1,441 shares at an exercise price of $298.48 per share, with the option vesting on the same schedule. Following these awards, he holds 1,582 shares of common stock directly, 1,441 stock options directly, and 3,500 shares of common stock indirectly through a trust for which his spouse is trustee.
ALNYLAM PHARMACEUTICALS, INC. director Stuart A. Arbuckle received equity awards on May 20, 2026. He was granted 671 restricted stock units, each representing one share of common stock, and a stock option for 1,441 shares at an exercise price of $298.48 per share. Both the RSUs and the option vest in full on the earlier of the first anniversary of the grant date or an earlier retirement or resignation that occurs no more than 90 days before that anniversary. Following these awards, Arbuckle holds 671 common shares and a vested-over-time option covering 1,441 underlying shares.
ALNYLAM PHARMACEUTICALS director Amy W. Schulman exercised stock options to acquire 11,250 shares of common stock at $70.20 per share. These options were due to expire on June 3, 2026, and the exercise occurred on May 13, 2026. Following the transaction, she directly holds 23,211 common shares. The corresponding stock option position for these 11,250 shares has been fully exercised, with no remaining options from this grant shown in the filing.
Capital World Investors reports beneficial ownership of 10,916,799 shares (8.2%) of Alnylam Pharmaceuticals. The filing states CWI has sole voting power over 10,871,837 shares and sole dispositive power over 10,916,799 shares of the 132,623,144 shares believed outstanding as of the filing. The amendment is signed by a CRMC officer.
Alnylam Pharmaceuticals reports a Schedule 13G/A filing showing Capital Research Global Investors holds 9,471,181 shares of common stock. The filing states this represents 7.1% of 132,623,144 shares outstanding. The filing lists 9,455,765 shares with sole voting power and 9,471,181 with sole dispositive power.
FMR LLC amended its Schedule 13G to report beneficial ownership of 14,640,524.87 shares of PHARMACEUTICALS INC common stock, representing 11.0% of the class as of 03/31/2026. The filing lists 14,103,896.98 shares with sole voting power and states ownership is held on behalf of multiple clients.
Alnylam Pharmaceuticals reported a strong turnaround for the quarter ended March 31, 2026. Total revenues rose to $1,167,175,000 from $594,189,000 a year earlier, driven mainly by net product revenues of $1,036,127,000, with AMVUTTRA contributing $889,931,000.
The company moved from a net loss of $18,251,000 to net income of $205,991,000, or $1.51 per diluted share, as higher sales outpaced increased research and development and selling, general and administrative expenses. Operating income rose to $268,636,000 from $18,077,000.
Alnylam ended the quarter with cash, cash equivalents and marketable debt securities totaling about $3.01 billion and total assets of $5,129,547,000. Stockholders’ equity increased to $1,075,380,000, while the company continued to carry convertible debt and significant liabilities related to the sale of future royalties and development funding.
Alnylam Pharmaceuticals reported a very strong first quarter of 2026, driven by its transthyretin (TTR) franchise. Total revenues nearly doubled to $1.17 billion, with net product revenues of $1.04 billion, up 121% from the same quarter in 2025.
The company swung from a GAAP net loss of $18.3 million in Q1 2025 to GAAP net income of $206.0 million, and non‑GAAP net income rose to $273.0 million. AMVUTTRA generated $889.9 million in sales, and total TTR net product revenues reached $910.4 million, a 153% increase. Rare disease products GIVLAARI and OXLUMO added $125.7 million, up 15%.
Alnylam reiterated its full‑year 2026 guidance, including total net product revenues of $4.9–$5.3 billion and non‑GAAP R&D and SG&A expenses of $2.7–$2.8 billion, while highlighting broad pipeline progress and upcoming clinical readouts in the second half of 2026.